Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial - Wikidata - wikimedia - TriplyDB

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

http://www.wikidata.org/entity/Q37278239

about

The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review Options for empagliflozin in combination therapy in type 2 diabetes mellitus Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes Empagliflozin Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Empagliflozin in the treatment of type 2 diabetes: evidence to date Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials Short commentary on empagliflozin and its potential clinical impact The role of empagliflozin in the management of type 2 diabetes by patient profile.Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview.Novel Agents for the Treatment of Type 2 Diabetes.Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis

P2860

Q24563917-235D6A5E-8E60-4323-8F84-D74253F5FA54 Q26745771-32DF929E-DC10-4B0E-ACA1-58E4AFF105B3 Q26749281-FD855CC9-463F-4805-9F45-F5A3EA4629BC Q26773311-7434B2DC-79A5-40C4-9B96-1665EF5FA595 Q26864336-FA0D54D1-CDF3-44DC-8E0A-64BA5DD5CAB7 Q27301948-B876A483-4047-4B9E-B1D2-73990125FA6F Q28072765-04168B5C-A8D3-4E31-A028-0507860260BE Q28080114-7023C5ED-C497-4F3E-B7D9-1DC1F87FA8E4 Q28553482-0BB40D5A-A340-49FD-84FA-F103C4C1756A Q30248634-048012C2-004D-4982-AC00-F23C4C8C2B74 Q30249371-0AD707EB-F621-4F82-950C-CAA719DF2208 Q31105792-A2C19C47-D7D6-4561-983F-9DF17AB9ED78 Q31112303-0C29CF61-D2AE-4702-9ECA-68EFD3F08102 Q32186373-F528D612-19F2-4255-AB39-2BB118345701 Q33812170-0ECC543B-51F7-4EB8-9FC8-2E7AC8B32F67 Q33837017-27878F1D-5C90-41C2-8D4C-51A285AEA67E Q33857698-0F9FFB60-F621-40FD-80C2-42E3BB263D94 Q33885732-93E104E9-EC0F-44DF-B3CC-002AFF9860D7 Q33890770-8AE984DE-518D-4539-ADD9-4AAFC989F411 Q34198692-CE8C1415-47DF-466A-AE5D-229DDC8F5591 Q34502358-CBD678A4-3CDA-4135-A65D-BF24A1FB8E69 Q34699217-3635919C-7194-42EA-B5D6-4B3DA844BDEA Q34973750-F9EB9151-24B9-48FF-ADA7-E37699083775 Q35117192-45D43F27-0B88-4897-97AF-19B08BF0B460 Q35157497-DA1A77EF-9F98-4C8F-B9C4-1E503D9E7805 Q35260544-255A60E3-0B40-489B-BC80-E4F9F407BCB7 Q35528797-9A38147B-B8F3-4ECA-910A-B4959E068C92 Q35592873-38C45237-3A6A-44DC-860B-AE1A692AE7D5 Q35780861-CF2E4CA0-7117-43AC-943D-3A6F29A6F160 Q35831426-B24BE56E-B9CE-44DA-BD74-11EEF28866D7 Q35910421-5C9F3EAF-8A8F-40AB-88D1-34F095CB03D0 Q36257565-1BD3402F-7434-400C-9B8F-870767B21920 Q36345951-220CB7AC-A18D-4DBB-BDD9-0EA46ED4EEB6 Q36402095-FA647714-B3DD-4D62-9630-884C9C717319 Q36555418-C715585A-2F29-4588-AF9C-CE3567763444 Q36592820-4B9DC122-C617-408D-B879-61C31759F48D Q36622125-F9C29BB3-7505-4E97-9BDF-14BE4C6DB34F Q36823710-541D26BA-4D0F-4C86-8FEF-4D9864E89CB0 Q36960633-19F2D027-2934-45E4-90F0-3ECF3165B3C0 Q37030680-461944EC-1960-4CD3-AED4-0B237DE72A14

P2860

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

http://www.wikidata.org/entity/Q37278239

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Empagliflozin as add-on to met ...... lind, placebo-controlled trial

@en

Empagliflozin as add-on to met ...... ind, placebo-controlled trial.

@nl

type

label

Empagliflozin as add-on to met ...... lind, placebo-controlled trial

@en

Empagliflozin as add-on to met ...... ind, placebo-controlled trial.

@nl

prefLabel

Empagliflozin as add-on to met ...... lind, placebo-controlled trial

@en

Empagliflozin as add-on to met ...... ind, placebo-controlled trial.

@nl

P1433

Q37278239-B133A182-FB2A-4AD5-80CC-672D083FDB50

P1476

Q37278239-608F0ADB-6D72-49A7-8C43-BE28D4EE2A40

P2093

Q37278239-0CF63627-3438-42E3-A509-C9FEB686F18D

Q37278239-3FC7B428-AB9B-430B-AD25-827A0F762A6B

Q37278239-4B7E2B3F-5C62-4686-92CF-14404538915C

Q37278239-4DD50068-F68B-4025-9C39-DEF7447071C6

Q37278239-ADC1259C-F062-4A77-89F8-8B11D089CBB7

Q37278239-BC836888-20A6-407F-A01E-332D1DE2757A

Q37278239-E82B8BAA-C250-4644-8709-290F14D3903B

P2860

Q37278239-0148B50E-03EB-4365-95C4-D950F003A199

Q37278239-03A35030-68BF-4E82-A90D-EB64272E1188

Q37278239-1B087E32-F5DA-4320-86D6-6D3123D39D3C

Q37278239-38790678-C08B-496C-AD85-F1D416DD9F1B

Q37278239-3B232939-1ED4-4ACD-9945-D2C0EBFA672F

Q37278239-46EF9270-4367-45BD-9F25-D5F71D627FB3

Q37278239-492BF357-6B83-4B34-9DC7-85619E665258

Q37278239-4997A0A6-AC2F-4642-8327-7C175DE722C6

Q37278239-50926A59-115F-4DD7-8884-BA7EC073170F

Q37278239-7E9A861E-E32F-42CD-89EA-3D55443E6302

P304

Q37278239-28FC52B1-1F38-4D5D-9D74-A8CB6A9630E3

P31

Q37278239-71E3C06F-8DB2-4739-B5F1-B0483182AB57

P356

Q37278239-8C3A9931-53DD-4306-935E-5F42255BEDD7

P407

Q37278239-0925C8B1-0503-41A3-A12B-C6FC9024764D

P433

Q37278239-6D2DCA79-C08C-4F07-BB77-D9B8FD3C0003

P478

Q37278239-39BBFCA7-E06A-4674-9CAC-6DC427702545

P50

Q37278239-10D4CDA2-B2EE-4592-B154-6C067285CAFB

P577

Q37278239-A44244A1-2944-470C-9CBC-28DE0BCDB4ED

P698

Q37278239-CD226937-871E-4C67-B599-3D1C0387D0A6

P921

Q37278239-4F7A9A90-1524-4214-8209-429534F5F8BE

Q37278239-B1F45313-3CDB-4521-AB38-4E726E541BD1

Q37278239-BBE6B932-CC65-482B-B3D1-B1410337C4BA

Q37278239-D529A98F-3A88-45F8-B05C-211B17A70519

P932

Q37278239-0C098AFE-F7E0-49EE-BAD8-74016DFC22D3

P356

P1433

P1476

Empagliflozin as add-on to met ...... lind, placebo-controlled trial

@en

P2093

EMPA-REG METSU Trial Investigators

http://www.w3.org/2001/XMLSchema#string

Elke Seewaldt-Becker

http://www.w3.org/2001/XMLSchema#string

Hans J Woerle

http://www.w3.org/2001/XMLSchema#string

Ludwig Merker

http://www.w3.org/2001/XMLSchema#string

Marc Weimer

http://www.w3.org/2001/XMLSchema#string

Thomas Meinicke

http://www.w3.org/2001/XMLSchema#string

Uli C Broedl

http://www.w3.org/2001/XMLSchema#string

P2860

Standards of medical care in diabetes--2012

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.

Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women.

Weight change in diabetes and glycemic and blood pressure control.

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.

Fate of the beta-cell in the pathophysiology of type 2 diabetes.

Renal glucose reabsorption inhibitors to treat diabetes.

P304

3396-3404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC12-2673

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Ulrich Häring

P577

2013-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23963895

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3816918

http://www.w3.org/2001/XMLSchema#string